Interferon beta-1a - Biogen

Drug Profile

Interferon beta-1a - Biogen

Alternative Names: Avonex; Avonex Pen; IFN-b-1a; Interferon β-1a

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biogen Idec
  • Developer Biogen; Nektar Therapeutics
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple sclerosis
  • Discontinued Chronic inflammatory demyelinating polyradiculoneuropathy; Glioma; Hepatitis B; Hepatitis C; Human papillomavirus infections; Pulmonary fibrosis; Ulcerative colitis

Most Recent Events

  • 31 Dec 2014 Biomarkers information updated
  • 31 Jan 2014 Interferon beta-1a licensed to UCB for commercialisation in South Korea, Hong Kong, Thailand, Singapore, Malaysia, Taiwan and for commercialisation and development in China
  • 14 May 2012 Avonex® Pen™ (intramuscular autoinjector for use with interferon beta-1a) and a dose-titration regimen using AVOSTART GRIP devices launched for Multiple sclerosis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top